This page has only limited features, please log in for full access.
In general, governments and health authorities have taken precautions during the COVID-19 pandemic to reduce the viral spread and protect vulnerable citizens. Patients with multiple myeloma (MM) have an increased risk of being infected with COVID-19 and developing a fatal course due to the related immunodeficiency. We investigated how Danish patients with MM reported their quality of life (QoL) pre-COVID and during COVID, in an ongoing longitudinal QoL survey. The responses given during the first and second wave of the COVID-19 pandemic were pooled, analyzed and compared to the same period the year before. We hypothesized that locking down the society would have caused deteriorated QoL and that patients living alone and those under the age of 65 would be particularly affected by the situation. Surprisingly, our study showed the opposite. Statistically significant and clinically relevant differences were primarily found during the first lock down and represented reduced fatigue, improved role functioning, decreased insomnia and improved physical health summaries in patients below 65 years of age. These results indicate that Danish patients with MM might have felt protected and safe by COVID restrictions. Otherwise, the questionaries used in QoL-MM survey may not have been able to capture the impact of the COVID-19 pandemic. Importantly, this indicates that QoL survey data obtained in clinical studies, in countries with highly developed health-care systems using standard questionnaires during the pandemic, allow room for interpretation without being adjusted for the impacts of the pandemic.
Louise Redder; Sören Möller; Anna Thit Johnsen; Mary Jarden; Christen Lykkegaard Andersen; Bo Amdi Jensen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard; Lene Kongsgaard Nielsen. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. COVID 2021, 1, 303 -314.
AMA StyleLouise Redder, Sören Möller, Anna Thit Johnsen, Mary Jarden, Christen Lykkegaard Andersen, Bo Amdi Jensen, Henrik Frederiksen, Henrik Gregersen, Anja Klostergaard, Morten Saaby Steffensen, Per Trøllund Pedersen, Maja Hinge, Mikael Frederiksen, Carsten Helleberg, Anne Kærsgaard Mylin, Niels Abildgaard, Lene Kongsgaard Nielsen. Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic. COVID. 2021; 1 (1):303-314.
Chicago/Turabian StyleLouise Redder; Sören Möller; Anna Thit Johnsen; Mary Jarden; Christen Lykkegaard Andersen; Bo Amdi Jensen; Henrik Frederiksen; Henrik Gregersen; Anja Klostergaard; Morten Saaby Steffensen; Per Trøllund Pedersen; Maja Hinge; Mikael Frederiksen; Carsten Helleberg; Anne Kærsgaard Mylin; Niels Abildgaard; Lene Kongsgaard Nielsen. 2021. "Quality of Life in Danish Patients with Multiple Myeloma during the COVID-19 Pandemic." COVID 1, no. 1: 303-314.
PURPOSE The majority of young adults with Hodgkin lymphoma (HL) are cured, but chemotherapy-induced infertility can have profound psychosocial consequences. Providing data on parenthood rates and use of assisted reproductive techniques (ARTs) after contemporary HL treatment is important for patient counseling and survivorship care. MATERIALS AND METHODS All Danish patients with HL diagnosed during 2000-2015 at the ages 18-40 years who achieved remission after first-line therapy were included and matched on age, sex, and parenthood status to five random persons from the general population. Parenthood rates were defined as the rate of first live birth per 1,000 person years, starting 9 months after HL diagnosis. Nationwide birth and patient registers were used to capture parenthood outcomes and ARTs use. RESULTS A total of 793 HL survivors and 3,965 comparators were included (median follow-up 8.7 years). Similar parenthood rates were observed for male and female HL survivors when compared with matched comparators (56.2 v 57.1; P = .871 for males and 63.8 v 61.2; P = .672 for females). For male HL survivors, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) therapy was associated with lower parenthood rates as compared to the matched comparators (28.1 v 60.8; P = .020). Live birth after ARTs were more common for HL survivors than for comparators (males 21.6% v 6.3%; P < .001; females 13.6% v 5.5%; P = .001). There were no differences in gestational age, Apgar score, or newborn measurements between HL survivors and matched comparators. CONCLUSION The parenthood rates for HL survivors who have not experienced relapse were generally similar to the general population. However, ARTs were used more often before the first live birth in HL survivors, which is relevant information when discussing possible long-term side effects and fertility-preserving treatment options.
Andreas K. Øvlisen; Lasse H. Jakobsen; Sandra Eloranta; Kristian H. Kragholm; Martin Hutchings; Henrik Frederiksen; Peter Kamper; Rasmus Bo Dahl-Sørensen; Danny Stoltenberg; Caroline E. Weibull; Joshua P. Entrop; Ingrid Glimelius; Karin E. Smedby; Christian Torp-Pedersen; Marianne T. Severinsen; Tarec C. El-Galaly. Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology 2021, JCO2100357 .
AMA StyleAndreas K. Øvlisen, Lasse H. Jakobsen, Sandra Eloranta, Kristian H. Kragholm, Martin Hutchings, Henrik Frederiksen, Peter Kamper, Rasmus Bo Dahl-Sørensen, Danny Stoltenberg, Caroline E. Weibull, Joshua P. Entrop, Ingrid Glimelius, Karin E. Smedby, Christian Torp-Pedersen, Marianne T. Severinsen, Tarec C. El-Galaly. Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. Journal of Clinical Oncology. 2021; ():JCO2100357.
Chicago/Turabian StyleAndreas K. Øvlisen; Lasse H. Jakobsen; Sandra Eloranta; Kristian H. Kragholm; Martin Hutchings; Henrik Frederiksen; Peter Kamper; Rasmus Bo Dahl-Sørensen; Danny Stoltenberg; Caroline E. Weibull; Joshua P. Entrop; Ingrid Glimelius; Karin E. Smedby; Christian Torp-Pedersen; Marianne T. Severinsen; Tarec C. El-Galaly. 2021. "Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study." Journal of Clinical Oncology , no. : JCO2100357.
We aimed to explore the genetic and environmental contributions to variation in the risk of hematologic malignancies and characterize familial dependence within and across hematologic malignancies. The study base included 316,397 individual twins from the Nordic Twin Study of Cancer with a median of 41 years of follow-up: 88,618 (28%) of the twins were monozygotic, and 3459 hematologic malignancies were reported. We estimated the cumulative incidence by age, familial risk, and genetic and environmental variance components of hematologic malignancies accounting for competing risk of death. The lifetime risk of any hematologic malignancy was 2.5% (95% CI 2.4–2.6%), as in the background population. This risk was elevated to 4.5% (95% CI 3.1–6.5%) conditional on hematologic malignancy in a dizygotic co-twin and was even greater at 7.6% (95% CI 4.8–11.8%) if a monozygotic co-twin had a hematologic malignancy. Heritability of the liability to develop any hematologic malignancy was 24% (95% CI 14–33%). This estimate decreased across age, from approximately 55% at age 40 to about 20–25% after age 55, when it seems to stabilize. In this largest ever studied twin cohort with the longest follow-up, we found evidence for familial risk of hematologic malignancies. The discovery of decreasing familial predisposition with increasing age underscores the importance of cancer surveillance in families with hematological malignancies.
Signe Clemmensen; Jennifer Harris; Jonas Mengel-From; Wagner Bonat; Henrik Frederiksen; Jaakko Kaprio; Jacob Hjelmborg. Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer. Cancers 2021, 13, 3023 .
AMA StyleSigne Clemmensen, Jennifer Harris, Jonas Mengel-From, Wagner Bonat, Henrik Frederiksen, Jaakko Kaprio, Jacob Hjelmborg. Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer. Cancers. 2021; 13 (12):3023.
Chicago/Turabian StyleSigne Clemmensen; Jennifer Harris; Jonas Mengel-From; Wagner Bonat; Henrik Frederiksen; Jaakko Kaprio; Jacob Hjelmborg. 2021. "Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer." Cancers 13, no. 12: 3023.
Dennis Lund Hansen; Sigbjørn Berentsen; Bruno Fattizzo; Pernille Lund Hansen; Wilma Barcellini; Henrik Frederiksen. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark , and Italy. American Journal of Hematology 2021, 96, 1 .
AMA StyleDennis Lund Hansen, Sigbjørn Berentsen, Bruno Fattizzo, Pernille Lund Hansen, Wilma Barcellini, Henrik Frederiksen. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark , and Italy. American Journal of Hematology. 2021; 96 (7):1.
Chicago/Turabian StyleDennis Lund Hansen; Sigbjørn Berentsen; Bruno Fattizzo; Pernille Lund Hansen; Wilma Barcellini; Henrik Frederiksen. 2021. "Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark , and Italy." American Journal of Hematology 96, no. 7: 1.
Objectives To examine predictors for bone marrow biopsy (BMB) and the outcome following BMB in patients with chronic immune thrombocytopenia (cITP). Methods We identified patients diagnosed with cITP during 2009‐2017 and obtained information on BMB, cITP treatment and subsequent thrombotic events, hospitalized bleeding, hematological cancer, and death using data from population‐based healthcare databases and medical records in Denmark, Norway, and Sweden. Results Among 4471 adults (≥18 years) with cITP, 1683 (37.6%) underwent BMB before cITP diagnosis, while cumulative BMB incidence after cITP diagnosis date was 3.1% at 1 year and 7.5% at 5 years. Predictors of having a BMB after cITP diagnosis included older age, male sex, low baseline platelet count, splenectomy, and number of cITP treatments. Compared with patients without BMB, patients with BMB had higher rates of thrombotic events (1 year adjusted hazard ratio [HR] 1.53 [95% CI, 0.92‐2.54]), hospitalized bleeding episodes (1 year adjusted HR 1.72 [95% CI, 1.15‐2.58]), hematological cancer (1 year adjusted HR 35.26 [95% CI 17.67‐70.34]), and all‐cause mortality (1 year adjusted HR 1.97 [95% CI, 1.44‐2.68]). Conclusion Patients who undergo BMB after cITP diagnosis represent a subset of patients with more severe disease and increased rates of complications as well as hematological malignancies.
Madeleine Andersson Gotschalck; Mette Nørgaard; Nickolaj Risbo; Christian Fynbo Christiansen; Shahram Bahmanyar; Waleed Ghanima; Naufil Alam; Henrik Frederiksen; Carrie M. Nielson; Henrik Toft Sørensen. Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia. European Journal of Haematology 2021, 107, 145 -156.
AMA StyleMadeleine Andersson Gotschalck, Mette Nørgaard, Nickolaj Risbo, Christian Fynbo Christiansen, Shahram Bahmanyar, Waleed Ghanima, Naufil Alam, Henrik Frederiksen, Carrie M. Nielson, Henrik Toft Sørensen. Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia. European Journal of Haematology. 2021; 107 (1):145-156.
Chicago/Turabian StyleMadeleine Andersson Gotschalck; Mette Nørgaard; Nickolaj Risbo; Christian Fynbo Christiansen; Shahram Bahmanyar; Waleed Ghanima; Naufil Alam; Henrik Frederiksen; Carrie M. Nielson; Henrik Toft Sørensen. 2021. "Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia." European Journal of Haematology 107, no. 1: 145-156.
During the COVID-19 pandemic, high-risk patient groups might have practiced social distancing and sheltering, and hospitals may have changed or postponed treatments and examinations. We aimed to explore health-related quality of life (QoL) in patients with haematological diseases during the early phase of the pandemic and their acceptability of using telehealth. We performed a cross-sectional survey among patients at the Department of Haematology, Odense University Hospital, Denmark. Eligible participants were patients receiving either active treatment or survivors in a follow-up program. The survey was open from 22 May to 13 June 2020. The survey contained questions on concerns and the impact of COVID-19 and acceptability on telehealth in addition to the assessment of health-related QoL. The later was assessed by the European Organisation for Research and Treatment of Cancer core QoL (EORTC QLQ-C30) questionnaire with the subdomains Global QoL, emotional functioning (EF) and social functioning (SF) being of primary interest. Further, anxiety during COVID-19 was assessed by use of an adapted version of the generalised anxiety disorder (GAD-7) questionnaire. 4420 patients were eligible to participate. The response rate was 53% (n = 2239) of which 37% where in a treatment program and 63% where in a follow-up program. The majority (80%) of patients were concerned about contracting COVID-19. The global QoL score (69.0, ±SD 22.6) was markedly lower than EF (84.5, ±SD 18.9) and SF (85.0, ±SD 23.4). Regression analysis showed that being concerned (a little, moderately, very, extremely) about contracting COVID-19 correlated with lower scores of global QoL (−3.86 to −22.76), EF (−3.81 to −26.41) and SF (−1.14 to −22.49). The GAD-7 score showed that approximately 20% of patients had symptoms of COVID-19 associated generalised anxiety. Finally, 67% of the patients were positive towards replacing face-to-face consultancies with phone calls, but video consultations were less preferred (47%). Danish patients with haematological cancer presented with low global QoL during the early phase of COVID-19, and 20% of the patients showed symptoms of generalised anxiety. Patients were overall positive towards the implementation of telehealth consultancies.
Charlotte Ellehuus; Stefan Starup Jeppesen; Lise Eckhoff; Hanne Vestergaard; Ditte Naundrup Therkildsen; Henrik Frederiksen; Henrik Rode Eshoj. Health-related quality of life of patients with haematologic cancer during COVID-19 and their opinions on telehealth consultations – a Danish single site cross-sectional survey. Acta Oncologica 2021, 1 -9.
AMA StyleCharlotte Ellehuus, Stefan Starup Jeppesen, Lise Eckhoff, Hanne Vestergaard, Ditte Naundrup Therkildsen, Henrik Frederiksen, Henrik Rode Eshoj. Health-related quality of life of patients with haematologic cancer during COVID-19 and their opinions on telehealth consultations – a Danish single site cross-sectional survey. Acta Oncologica. 2021; ():1-9.
Chicago/Turabian StyleCharlotte Ellehuus; Stefan Starup Jeppesen; Lise Eckhoff; Hanne Vestergaard; Ditte Naundrup Therkildsen; Henrik Frederiksen; Henrik Rode Eshoj. 2021. "Health-related quality of life of patients with haematologic cancer during COVID-19 and their opinions on telehealth consultations – a Danish single site cross-sectional survey." Acta Oncologica , no. : 1-9.
Background: Warm autoimmune haemolytic anaemia (wAIHA) is a haemolytic disorder, most commonly seen among adults and is classified as either primary or secondary to an underlying disease. We describe the age and sex distribution and the proportion of secondary wAIHA. Method: We retrieved 2635 published articles, screened abstracts and titles, and identified 27 articles eligible for full-text review. From these studies, we extracted data regarding number of patients, sex distribution, age at diagnosis, number of patients with secondary wAIHA, and whether the patients were diagnosed through local or referral centres. All data were weighted according to the number of included patients in each study. Results: 27 studies including a total of 4311 patients with wAIHA, of which 66% were females, were included. The median age at diagnosis was 68.7 years, however, wAIHA affected all ages. The mean proportion of secondary wAIHA was 49%, most frequently secondary to systemic lupus erythematosus. The proportions of secondary wAIHA reported from primary vs. referral centres were 35% vs. 59%, respectively. Conclusion: This review consolidates previously reported gender distribution. The higher proportion of secondary wAIHA in referral centres suggests that the most severely affected patients are disproportionally more frequent in such facilities.
Stinne Tranekær; Dennis Hansen; Henrik Frederiksen. Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia—A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 2021, 10, 1244 .
AMA StyleStinne Tranekær, Dennis Hansen, Henrik Frederiksen. Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia—A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2021; 10 (6):1244.
Chicago/Turabian StyleStinne Tranekær; Dennis Hansen; Henrik Frederiksen. 2021. "Epidemiology of Secondary Warm Autoimmune Haemolytic Anaemia—A Systematic Review and Meta-Analysis." Journal of Clinical Medicine 10, no. 6: 1244.
Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis. This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study’s primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen. A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% (n = 61) and 21% of the patients had died and 14 of the 23 deceased cancer patients were ≥70 years. Most patients were classified with mild COVID-19 symptoms (66%, n = 74); however, 48% (n = 23) of the ≥70-year-olds patients were classified with severe or critical COVID-19 symptoms. Among the total study population, 61% (n = 68) had comorbidities and comorbidity were more frequently observed among the deceased (91%, n = 21) and older cancer patients (≥70 years, 81%, n = 39). Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.
S. Ehmsen; L. H. Jakobsen; M. E. Lendorf; R. L. Eefsen; L. Bentsen; A. S. Knoop; N. Aggerholm-Pedersen; H. Skuladottir; J. Herrstedt; L. H. Jensen; C. Rotbøl; M. B. Damm; K. Wedervang; A. Glenthøj; J. Ryg; H. Frederiksen; A. R. Kodahl. Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study. Acta Oncologica 2021, 1 -7.
AMA StyleS. Ehmsen, L. H. Jakobsen, M. E. Lendorf, R. L. Eefsen, L. Bentsen, A. S. Knoop, N. Aggerholm-Pedersen, H. Skuladottir, J. Herrstedt, L. H. Jensen, C. Rotbøl, M. B. Damm, K. Wedervang, A. Glenthøj, J. Ryg, H. Frederiksen, A. R. Kodahl. Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study. Acta Oncologica. 2021; ():1-7.
Chicago/Turabian StyleS. Ehmsen; L. H. Jakobsen; M. E. Lendorf; R. L. Eefsen; L. Bentsen; A. S. Knoop; N. Aggerholm-Pedersen; H. Skuladottir; J. Herrstedt; L. H. Jensen; C. Rotbøl; M. B. Damm; K. Wedervang; A. Glenthøj; J. Ryg; H. Frederiksen; A. R. Kodahl. 2021. "Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study." Acta Oncologica , no. : 1-7.
Henry Jensen; Henrik Frederiksen. Balance on slack line; diagnostic intensity and patient safety during the SARS-CoV-2 pandemic. Acta Oncologica 2021, 60, 1 -3.
AMA StyleHenry Jensen, Henrik Frederiksen. Balance on slack line; diagnostic intensity and patient safety during the SARS-CoV-2 pandemic. Acta Oncologica. 2021; 60 (1):1-3.
Chicago/Turabian StyleHenry Jensen; Henrik Frederiksen. 2021. "Balance on slack line; diagnostic intensity and patient safety during the SARS-CoV-2 pandemic." Acta Oncologica 60, no. 1: 1-3.
In the past decade, several studies have reported that patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of second solid cancer or lymphoid hematological cancer. In this qualitative review study, we present results from studies that report on these cancer risks in comparison to cancer incidences in the general population or a control group. Our literature search identified 12 such studies published in the period 2009–2018 including analysis of more than 65,000 patients. The results showed that risk of solid cancer is 1.5- to 3.0-fold elevated and the risk of lymphoid hematological cancer is 2.5- to 3.5-fold elevated in patients with MPNs compared to the general population. These elevated risks apply to all MPN subtypes. For solid cancers, particularly risks of skin cancer, lung cancer, thyroid cancer, and kidney cancer are elevated. The largest difference in cancer risk between patients with MPN and the general population is seen in patients below 80 years. Cancer prognosis is negatively affected due to cardiovascular events, thrombosis, and infections by a concurrent MPN diagnosis mainly among patients with localized cancer. Our review emphasizes that clinicians caring for patients with MPNs should be aware of the very well-documented increased risk of second non-myeloid cancers.
Mette Brabrand; Henrik Frederiksen. Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers 2020, 12, 3061 .
AMA StyleMette Brabrand, Henrik Frederiksen. Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications. Cancers. 2020; 12 (10):3061.
Chicago/Turabian StyleMette Brabrand; Henrik Frederiksen. 2020. "Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications." Cancers 12, no. 10: 3061.
An association between hematological cancers and inflammatory bowel disease (IBD) has previously been suggested, but the risk of IBD in patients with myeloproliferative neoplasms (MPNs) is unknown. We conducted a nationwide population-based cohort study using Danish registries, to estimate the risk of IBD in individuals diagnosed with essential thrombocythemia, polycythemia vera, myelofibrosis or unclassifiable MPN during 1994–2013. MPN patients were matched 1:10 with sex- and age-matched comparisons. Everyone was followed until a diagnosis of IBD, death/emigration, or 31 December 2013. The risk of IBD overall and according to MPN subtype was calculated using Cox regression and presented as hazard ratios (HRs) with 95% confidence intervals (CI). Of 8207 MPN patients followed for 45,232 person-years, 80 were diagnosed with IBD (61 ulcerative colitis, 19 Crohn’s disease). The rate of IBD per 1000 person-years was 1.8 (95% CI:1.4–2.2) in patients vs. 0.8 (95% CI:0.7–0.8) in comparisons, and the absolute 10-year risk of IBD was 0.8% (95% CI:0.6–1.0) in patients vs. 0.4% (95% CI:0.4–0.5) in comparisons. The HR of IBD was 2.4 (95% CI:2.1–2.9) with similar HRs for ulcerative colitis and Crohn’s disease. MPN subtype risks varied from 2.1 (95% CI:1.6–2.7) to 2.8 (95% CI:2.1–3.7). Our unselected cohort study showed a more than 2-fold increased risk of IBD in MPN patients.
Marie Bak; Tine Jess; Esben Meulengracht Flachs; Ann-Dorthe Zwisler; Knud Juel; Henrik Frederiksen. Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study. Cancers 2020, 12, 2700 .
AMA StyleMarie Bak, Tine Jess, Esben Meulengracht Flachs, Ann-Dorthe Zwisler, Knud Juel, Henrik Frederiksen. Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study. Cancers. 2020; 12 (9):2700.
Chicago/Turabian StyleMarie Bak; Tine Jess; Esben Meulengracht Flachs; Ann-Dorthe Zwisler; Knud Juel; Henrik Frederiksen. 2020. "Risk of Inflammatory Bowel Disease in Patients with Chronic Myeloproliferative Neoplasms: A Danish Nationwide Cohort Study." Cancers 12, no. 9: 2700.
Objectives Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, however this is unknown. Methods We conducted a prospective, nationwide study including 66 patients in follow‐up at Danish haematology departments with a malignant or non‐malignant haematological disorder and with verified SARS‐CoV‐2 infection. Outcomes were intensive care unit (ICU) admission and one‐month survival rate. Results Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%), and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6%, and hypogammaglobulinaemia in 26·3%. The SARS‐CoV‐2 infection was mild in 50·0%, severe in 36·4%, and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS‐CoV‐2 infection, high comorbidity score or high performance status score, purine analogue treatment, and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients. Conclusion Haematological patients with SARS‐CoV‐2 infection has a severe clinical.
Andreas Glenthøj; Lasse H. Jakobsen; Henrik Sengeløv; Syed A. Ahmad; Kristian Qvist; Annika Rewes; Christian B. Poulsen; Ulrik M. Overgaard; Ingolf Mølle; Marianne Tang Severinsen; Casper N. Strandholdt; Jack Maibom; Annette R. Kodahl; Jesper Ryg; Pernille Ravn; Isik S. Johansen; Søren N. Helsø; Søren Jensen‐Fangel; Jacek Kisielewicz; Lothar Wiese; Marie Helleberg; Ole Kirk; Michael R. Clausen; Henrik Frederiksen. SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study. European Journal of Haematology 2020, 106, 72 -81.
AMA StyleAndreas Glenthøj, Lasse H. Jakobsen, Henrik Sengeløv, Syed A. Ahmad, Kristian Qvist, Annika Rewes, Christian B. Poulsen, Ulrik M. Overgaard, Ingolf Mølle, Marianne Tang Severinsen, Casper N. Strandholdt, Jack Maibom, Annette R. Kodahl, Jesper Ryg, Pernille Ravn, Isik S. Johansen, Søren N. Helsø, Søren Jensen‐Fangel, Jacek Kisielewicz, Lothar Wiese, Marie Helleberg, Ole Kirk, Michael R. Clausen, Henrik Frederiksen. SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study. European Journal of Haematology. 2020; 106 (1):72-81.
Chicago/Turabian StyleAndreas Glenthøj; Lasse H. Jakobsen; Henrik Sengeløv; Syed A. Ahmad; Kristian Qvist; Annika Rewes; Christian B. Poulsen; Ulrik M. Overgaard; Ingolf Mølle; Marianne Tang Severinsen; Casper N. Strandholdt; Jack Maibom; Annette R. Kodahl; Jesper Ryg; Pernille Ravn; Isik S. Johansen; Søren N. Helsø; Søren Jensen‐Fangel; Jacek Kisielewicz; Lothar Wiese; Marie Helleberg; Ole Kirk; Michael R. Clausen; Henrik Frederiksen. 2020. "SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study." European Journal of Haematology 106, no. 1: 72-81.
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front‐line setting and as later‐line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population‐based level are still limited. Objectives To report outcomes and AEs in a population‐based cohort treated with ibrutinib outside clinical trials. Methods We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. Results In total, 205 patients were included of whom 39 (19%) were treatment‐naïve. The median follow‐up was 21.4 months (IQR, 11.9‐32.8), and the estimated overall survival at 12 months was 88.8% (95%CI: 84.3‐93.3) and the estimated progression‐free survival at 12 months was 86.3% (95% CI: 81.3‐91.2%). During follow‐up, 200 (97.6%) patients had at least one AE and 100 (48.8%) patients had at least one grade grade ≥3 AE. Eigthy‐six patients (42.0%) discontinued ibrutinib, hereof 47 (54.7%) due to AEs and 19 (22.1%) had progression of CLL or Richter transformation. Conclusions In our study, we find comparable, though slightly inferior, overall and progression‐free survival, but discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.
Kathrine Aarup; Emelie Rotbain; Lisbeth Enggaard; Robert Schou Pedersen; Olav Jonas Bergmann; Rasmus Heje Thomsen; Mikael Frederiksen; Henrik Frederiksen; Tine Nielsen; Ilse Christiansen; Michael Asger Andersen; Carsten Utoft Niemann. Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. European Journal of Haematology 2020, 105, 646 -654.
AMA StyleKathrine Aarup, Emelie Rotbain, Lisbeth Enggaard, Robert Schou Pedersen, Olav Jonas Bergmann, Rasmus Heje Thomsen, Mikael Frederiksen, Henrik Frederiksen, Tine Nielsen, Ilse Christiansen, Michael Asger Andersen, Carsten Utoft Niemann. Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. European Journal of Haematology. 2020; 105 (5):646-654.
Chicago/Turabian StyleKathrine Aarup; Emelie Rotbain; Lisbeth Enggaard; Robert Schou Pedersen; Olav Jonas Bergmann; Rasmus Heje Thomsen; Mikael Frederiksen; Henrik Frederiksen; Tine Nielsen; Ilse Christiansen; Michael Asger Andersen; Carsten Utoft Niemann. 2020. "Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib." European Journal of Haematology 105, no. 5: 646-654.
In 2019 the UK Myeloma Research Alliance introduced the Myeloma Risk Profile (MRP) for prediction of outcome in patients with newly diagnosed multiple myeloma (MM), ineligible for autologous stem cell transplantation. To validate the MRP in a population‐based setting we performed a study of the entire cohort of transplant ineligible MM patients above 65 years in the Danish National MM Registry. Our data confirmed the value of the MRP. In a cohort of 1,377 patients, the MRP score separated patients into three distinct risk‐groups with an observed hazard ratio of 2.91 for early death in high‐risk versus low‐risk patients.
Louise Redder; Tobias W. Klausen; Annette Juul Vangsted; Henrik Gregersen; Niels F. Andersen; Robert S. Pedersen; Agoston G. Szabo; Mikael Frederiksen; Ulf C. Frølund; Carsten Helleberg; Lene Kongsgaard Nielsen; Per T. Pedersen; Morten Salomo; Peter Gimsing; Henrik Frederiksen; Niels Abildgaard. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry. British Journal of Haematology 2020, 193, 119 -124.
AMA StyleLouise Redder, Tobias W. Klausen, Annette Juul Vangsted, Henrik Gregersen, Niels F. Andersen, Robert S. Pedersen, Agoston G. Szabo, Mikael Frederiksen, Ulf C. Frølund, Carsten Helleberg, Lene Kongsgaard Nielsen, Per T. Pedersen, Morten Salomo, Peter Gimsing, Henrik Frederiksen, Niels Abildgaard. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry. British Journal of Haematology. 2020; 193 (1):119-124.
Chicago/Turabian StyleLouise Redder; Tobias W. Klausen; Annette Juul Vangsted; Henrik Gregersen; Niels F. Andersen; Robert S. Pedersen; Agoston G. Szabo; Mikael Frederiksen; Ulf C. Frølund; Carsten Helleberg; Lene Kongsgaard Nielsen; Per T. Pedersen; Morten Salomo; Peter Gimsing; Henrik Frederiksen; Niels Abildgaard. 2020. "Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population‐based study from the Danish national multiple myeloma registry." British Journal of Haematology 193, no. 1: 119-124.
Many factors contribute to the plasma albumin (PA) level. We aimed to quantify different factors’ relative contribution to the PA level when diagnosing hematological malignancy (HM). The study was a population-based registry study including patients with HM in a Danish region. We applied multivariate linear regression analyses with C-reactive protein (CRP), WHO performance score (WHO-PS), age, sex, comorbidity, and HM type as exposures and the PA level on the day of the HM diagnosis (DX) as the outcome. The relative contribution of each exposure was determined as a percentage of the models’ coefficient of determination (R2). In total, 2528 patients with HM had PA measured on DX. In the model comprising all exposures, CRP contributed with 65.8% to the R2 of 0.389 whereas 3 variables (CRP, WHO-PS, HM type) together contributed with 96.1%. When CRP was excluded from the model, R2 declined to 0.215 and the WHO-PS contributed with 96%. Other models, including separate analyses for each HM type, corroborated these results, except in myeloma patients where WHO-PS contributed with 61.1% to the R2 of 0.234. The inflammation biomarker CRP was the main predictor of the PA level on DX. The WHO-PS also contributed to the PA level on DX whereas the remaining factors (HM type, age, sex, and comorbidity) were of much less importance.
Kim Oren Gradel; Henriette Engberg; Fernando G. Zampieri; Pedro Póvoa; Simone F. Simonsen; Pernille Just Vinholt; Olav Sivertsen Garvik; Pernille S. Ljungdalh; Henrik Frederiksen. Contributing factors to the plasma albumin level at diagnosis of hematological malignancy. Hospital Practice 2020, 48, 223 -229.
AMA StyleKim Oren Gradel, Henriette Engberg, Fernando G. Zampieri, Pedro Póvoa, Simone F. Simonsen, Pernille Just Vinholt, Olav Sivertsen Garvik, Pernille S. Ljungdalh, Henrik Frederiksen. Contributing factors to the plasma albumin level at diagnosis of hematological malignancy. Hospital Practice. 2020; 48 (4):223-229.
Chicago/Turabian StyleKim Oren Gradel; Henriette Engberg; Fernando G. Zampieri; Pedro Póvoa; Simone F. Simonsen; Pernille Just Vinholt; Olav Sivertsen Garvik; Pernille S. Ljungdalh; Henrik Frederiksen. 2020. "Contributing factors to the plasma albumin level at diagnosis of hematological malignancy." Hospital Practice 48, no. 4: 223-229.
Background and Aim: Based on advances in the diagnosis, classification, and management of diffuse large B-cell lymphoma (DLBCL), a number of new prognostic models have been proposed. The aim of this study was to review and compare different prognostic models of DLBCL based on the statistical methods used to evaluate the performance of each model, as well as to analyze the possible limitations of the methods. Methods and Results: A literature search identified 46 articles that proposed 55 different prognostic models for DLBCL by combining different clinical, laboratory, and other parameters of prognostic significance. In addition, six studies used nomograms, which avoid risk categorization, to create prognostic models. Only a minority of studies assessed discrimination and/or calibration to compare existing models built upon different statistical methods in the process of development of a new prognostic model. All models based on nomograms reported the c-index as a measure of discrimination. There was no uniform evaluation of the performance in other prognostic models. We compared these models of DLBCL by calculating differences and ratios of 3-year overall survival probabilities between the high- and the low-risk groups. We found that the highest and lowest ratio between low- and high-risk groups was 6 and 1.31, respectively, while the difference between these groups was 18.9% and 100%, respectively. However, these studies had limited duration of follow-up and the number of patients ranged from 71 to 335. Conclusion: There is no universal statistical instrument that could facilitate a comparison of prognostic models in DLBCL. However, when developing a prognostic model, it is recommended to report its discrimination and calibration in order to facilitate comparisons between different models. Furthermore, prognostic models based on nomograms are becoming more appealing owing to individualized disease-related risk estimations. However, they have not been validated yet in other study populations.
Jelena Jelicic; Thomas Stauffer Larsen; Henrik Frederiksen; Bosko Andjelic; Milos Maksimovic; Zoran Bukumiric. Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models – A Systematic Review. Clinical Epidemiology 2020, ume 12, 537 -555.
AMA StyleJelena Jelicic, Thomas Stauffer Larsen, Henrik Frederiksen, Bosko Andjelic, Milos Maksimovic, Zoran Bukumiric. Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models – A Systematic Review. Clinical Epidemiology. 2020; ume 12 ():537-555.
Chicago/Turabian StyleJelena Jelicic; Thomas Stauffer Larsen; Henrik Frederiksen; Bosko Andjelic; Milos Maksimovic; Zoran Bukumiric. 2020. "Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models – A Systematic Review." Clinical Epidemiology ume 12, no. : 537-555.
Background: Congenital red blood cell (RBC) disorders, such as hemoglobinopathies, are frequent worldwide but with large geographical variation. Growing migration has increased the number of patients with RBC disorders in formerly low prevalence countries, eg, Denmark. However, accurate prevalences are unknown. Methods: Patients with a registered diagnosis of congenital hemolysis in the Danish National Patient Register between 1977 and 2016 were linked to a national laboratory database of RBC disorders and the Danish civil registration system. We calculate annual age- and sex-specific prevalences of the congenital hemolytic disorders from 2000 to 2016. Results: Prevalences of all subtypes of congenital hemolytic disorders increased during the study period. The prevalence of hereditary spherocytosis increased 1.73 times between 2000 and 2015, from 10.2/105 persons to 17.7/105 persons. Alpha thalassemia trait had a prevalence of 0.5/105 persons in 2000, but increased 41 times to 19.2/105 persons in 2015. Beta thalassemia minor increased eightfold from 4.5/105 persons in 2000 to 34.9/105 persons in 2015. Likewise, sickle cell trait increased 11 times from 0.7/105 persons in 2000 to 8.1/105 persons in 2015, whereas sickle cell disease increased from 0.5/105 persons to 2.7/105 persons in 2015, a fivefold increase. Conclusion: The prevalence of congenital RBC disorders in Denmark is increasing. The hemoglobinopathy traits now have prevalences as high as hereditary spherocytosis. These estimates of congenital hemolytic disorders in Denmark emphasize that inborn hemoglobin disorders are a public health concern, even in some formerly low prevalence countries.
Dennis Lund Hansen; Andreas Glenthøj; Sören Möller; Bart J Biemond; Kjeld Andersen; David Gaist; Jesper Brix Petersen; Henrik Frederiksen. Prevalence of Congenital Hemolytic Disorders in Denmark, 2000–2016. Clinical Epidemiology 2020, ume 12, 485 -495.
AMA StyleDennis Lund Hansen, Andreas Glenthøj, Sören Möller, Bart J Biemond, Kjeld Andersen, David Gaist, Jesper Brix Petersen, Henrik Frederiksen. Prevalence of Congenital Hemolytic Disorders in Denmark, 2000–2016. Clinical Epidemiology. 2020; ume 12 ():485-495.
Chicago/Turabian StyleDennis Lund Hansen; Andreas Glenthøj; Sören Möller; Bart J Biemond; Kjeld Andersen; David Gaist; Jesper Brix Petersen; Henrik Frederiksen. 2020. "Prevalence of Congenital Hemolytic Disorders in Denmark, 2000–2016." Clinical Epidemiology ume 12, no. : 485-495.
Background: Acquired hemolytic disorders—autoimmune hemolytic anemia (AIHA), cold agglutinin disease (CAD), paroxysmal nocturnal hemoglobinuria (PNH), drug-induced hemolysis (DIHA), and acquired hemolysis not otherwise specified (AHNOS)—are considered rare. Despite their potentially major health implications, data regarding their incidence and prevalence are scarce. Methods: To fill this gap we collected data regarding all patients with acquired hemolytic disorder diagnoses in 1977– 2016 from the Danish National Patient Register. These data were linked with vital and migration status information from the Danish Civil Registration System. From these data combined with annual demographic data for the background population, we calculated age- and sex-specific incidence rates and prevalence proportions of acquired hemolytic disorders for specified time periods. Results: Our analysis included 5868 patients with acquired hemolytic disorders (2715 with AIHA, 112 CAD, 397 DIHA, 116 PNH, and 2154 AHNOS). The incidence rates per 100 000 person-years in 1980– 1993 and 2008– 2016 were 0.81 and 1.77 for AIHA, 0.31 and 0.12 for DIHA, and 0.04 and 0.08 for PNH, respectively. The 2008– 2016 CAD incidence rate was 0.18/100 000 person-years, CAD diagnosis code was not defined before 1994. All incidence rates increased with age. The prevalence proportion per 100 000 persons in 1980 and 2015 was 2.52 and 17.01 for AIHA, 0.80 and 1.50 for DIHA, and 0.18 and 1.04 for PNH. CAD prevalence in 2015 was 1.04/100 000 persons. Conclusion: Acquired hemolytic anemia incidence rates and prevalence proportions with the exception of DIHA are markedly increasing.
Dennis Lund Hansen; Sören Möller; Kjeld Andersen; David Gaist; Henrik Frederiksen. Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980–2016. Clinical Epidemiology 2020, ume 12, 497 -508.
AMA StyleDennis Lund Hansen, Sören Möller, Kjeld Andersen, David Gaist, Henrik Frederiksen. Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980–2016. Clinical Epidemiology. 2020; ume 12 ():497-508.
Chicago/Turabian StyleDennis Lund Hansen; Sören Möller; Kjeld Andersen; David Gaist; Henrik Frederiksen. 2020. "Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980–2016." Clinical Epidemiology ume 12, no. : 497-508.
Bruno Fattizzo; Marc Michel; Anna Zaninoni; Juri Giannotta; Stephanie Guillet; Henrik Frederiksen; Josephine M.I. Vos; Francesca R. Mauro; Bernd Jilma; Andrea Patriarca; Francesco Zaja; Anita Hill; Sigbiørn Berentsen; Wilma Barcellini. Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. Haematologica 2020, 106, 622 -625.
AMA StyleBruno Fattizzo, Marc Michel, Anna Zaninoni, Juri Giannotta, Stephanie Guillet, Henrik Frederiksen, Josephine M.I. Vos, Francesca R. Mauro, Bernd Jilma, Andrea Patriarca, Francesco Zaja, Anita Hill, Sigbiørn Berentsen, Wilma Barcellini. Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. Haematologica. 2020; 106 (2):622-625.
Chicago/Turabian StyleBruno Fattizzo; Marc Michel; Anna Zaninoni; Juri Giannotta; Stephanie Guillet; Henrik Frederiksen; Josephine M.I. Vos; Francesca R. Mauro; Bernd Jilma; Andrea Patriarca; Francesco Zaja; Anita Hill; Sigbiørn Berentsen; Wilma Barcellini. 2020. "Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study." Haematologica 106, no. 2: 622-625.
Cancer‐related psychological distress may lead to depression and anxiety among survivors. The vast majority of patients with Hodgkin lymphoma (HL) become long‐term survivors, but the risk of mental health problems after HL is not well‐characterized. Using national population‐based registries, we investigated the cumulative incidence of psychotropic drug (antidepressants, antipsychotics, and anxiolytics) use (proxies for depression and anxiety) in HL patients as well as if an increased risk would normalize over time for patients in remission. The study included 945 HL patients aged 18‐92 years and 4725 matched persons. In total, 215 HL patients (22.8%) received a prescription of any psychotropic drug (PD) at some point after date of diagnosis compared to 545 persons (11.5%) in the matched cohort. Cumulative incidences with death/relapse as competing risk confirmed that HL patients were at higher risk of receiving psychotropic drug prescriptions, but the increased risk was transient and normalized to the matched population 5 years into survivorship. Increased age, Eastern Cooperative Oncology Group performance status, and disease stage were associated with higher risk of psychotropic drug prescriptions. Given the increased rate of psychotropic drug prescriptions after HL diagnosis, screening for symptoms of depression and anxiety is warranted after HL diagnosis and first years into survivorship.
Andreas K. Øvlisen; Lasse H. Jakobsen; Kristian H. Kragholm; René E. Nielsen; Martin Hutchings; Rasmus B. Dahl‐Sørensen; Henrik Frederiksen; Danny Stoltenberg; Martin Bøgsted; Lene Sofie Granfeldt Østgård; Marianne Tang Severinsen; Tarec C. El‐Galaly. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Medicine 2020, 9, 4395 -4404.
AMA StyleAndreas K. Øvlisen, Lasse H. Jakobsen, Kristian H. Kragholm, René E. Nielsen, Martin Hutchings, Rasmus B. Dahl‐Sørensen, Henrik Frederiksen, Danny Stoltenberg, Martin Bøgsted, Lene Sofie Granfeldt Østgård, Marianne Tang Severinsen, Tarec C. El‐Galaly. Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. Cancer Medicine. 2020; 9 (12):4395-4404.
Chicago/Turabian StyleAndreas K. Øvlisen; Lasse H. Jakobsen; Kristian H. Kragholm; René E. Nielsen; Martin Hutchings; Rasmus B. Dahl‐Sørensen; Henrik Frederiksen; Danny Stoltenberg; Martin Bøgsted; Lene Sofie Granfeldt Østgård; Marianne Tang Severinsen; Tarec C. El‐Galaly. 2020. "Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients." Cancer Medicine 9, no. 12: 4395-4404.